Status:
COMPLETED
Can Probiotic Vivomixx Eradicate Colonization With ESBL?
Lead Sponsor:
Lund University
Conditions:
Antibiotic Resistant Infection
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
Can probiotic Vivomixx eradicate Extended Spectrum BetaLactam (ESBL) colonization in adult patients?
Detailed Description
Infections due to extended spectrum cephalosporin-resistant Enterobacteriaceae (ESCRE) are a widely recognized public health threat. The prevalence of ESCRE is comparably low in Sweden but is steadily...
Eligibility Criteria
Inclusion
- Chronic (more than three months) ESBL colonization of the same strain as determined by
- species, phenotype and antibiogram.
- Patients must be able to swallow sachets.
- Must be able to speak and understand Swedish.
- Must have a permanent residence in Sweden.
- Must be able to sign informed consent in Swedish.
Exclusion
- Immunosuppression (i.e. chemotheraphy, treatment with TNF-alpha-inhibitors).
- In patient care.
- immunodeficiency
- psychiatric disorder
- alcohol or substance abuse
- dementia
- Invasive catheters.
Key Trial Info
Start Date :
February 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2019
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03860415
Start Date
February 1 2017
End Date
April 30 2019
Last Update
May 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oskar Ljungquist
Helsingborg, Skåne County, Sweden, 25187